ArticleThe clinical respiratory journal2026
Growth Differentiation Factor-15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid-Containing Regimen.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLinezolid effectively treats rifampicin-resistant tuberculosis (RR-TB) but can cause significant hematological toxicities linked to mitochondrial dysfunction in hematopoietic stem cells. Growth differentiation factor-15 (GDF-15) has been identified as a potential biomarker of this dysfunction. This study aimed to determine whether baseline GDF-15 levels can predict myelosuppression in RR-TB patients treated with linezolid.
methodsThe study included patients with RR-TB from three referral hospitals who were treated with a linezolid-containing regimen for at least 4 weeks. Hematological parameters and GDF-15 levels were measured at baseline as well as at the 2nd and 4th-8th weeks of treatment.
resultsNinety-seven subjects were included in this study. By the 2nd week of linezolid treatment, GDF-15 levels significantly increased from a baseline of 635.58 (407.31-1583.65) to 708.96 (378.09-2408.89)pg/ml (p = 0.003). By weeks 4-8, 65% of patients developed myelosuppression. A correlation was found between baseline GDF-15 levels and hemoglobin reduction at weeks 4-8 (r = 0.4, p < 0.001). Baseline GDF-15 levels > 950 pg/mL identified patients with more than a 25% reduction in hemoglobin (AUC 0.756, 95% CI 0.659-0.838).
conclusionBaseline GDF-15 levels were correlated with hemoglobin changes during the 4th-8th weeks of linezolid treatment. These levels can predict myelosuppression, particularly hemoglobin changes, in patients with RR-TB undergoing long-term linezolid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.